{
    "nctId": "NCT01479036",
    "briefTitle": "Trial of Neoadjuvant Endostar, Docetaxel and Epirubicin for Patients With Breast Cancer",
    "officialTitle": "Phase \u2162 Trial of Neoadjuvant Recombinant Human Endostatin, Docetaxel and Epirubicin as First-Line Therapy in Patients With Breast Cancer",
    "overallStatus": "UNKNOWN",
    "conditions": "Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE3",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 800,
    "primaryOutcomeMeasure": "Clinical/pathological response",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Histologically confirmed invasive breast cancer (core needle biopsy for breast cancer diagnosis and fine needle aspiration for lymph node metastasis diagnosis)\n* Stage \u2161A-\u2162C\n* Age 18-70\n* ECOG performance status 0-2\n* No evidence of distant metastasis\n* No previous therapy\n* Normal hematologic function\n* left ventricular ejection fraction greater than 50 percent\n* No abnormality of renal or liver function\n* Written informed consent\n\nExclusion Criteria:\n\n* With allergic constitution or possible allergic reflection to drugs to be used in this study\n* Any concurrent uncontrolled medical or psychiatric disorder\n* History of severe heart diseases, including congestive heart failure, unstable angina, uncontrolled arrhythmia, myocardial infarction, uncontrolled high blood pressure, or heart valve disease.\n* History of bleeding diathesis\n* Being pregnant or nursing",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}